Details for Patent: 8,449,867

Title:	Microemulsion and sub-micron emulsion process and compositions
Abstract:	An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.
Inventor(s):	Larm; Maria Graziella (Rosanna, AU), Harding; Ronald (North Warrandyte, AU), Johnston; Michael (Yarraville, AU), Abram; Albert Zorko (Wantirna, AU), Vijayakumar; Prema (Fremont, CA), Sun; Phoebe (Mountain View, CA)
Assignee:	Stiefel Research Australia Pty Ltd (Rowville, AU)
Filing Date:	Jun 25, 2009
Application Number:	12/457,953
Claims:	1. A process for the preparation of an oil in water (O/W) microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, the method comprising the successive steps of: a) admixing a first part comprising at least one selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant, and a second part comprising water and at least one hydrophilic surfactant to achieve homogeneity, b) heating the mix of step a) to a phase assembly temperature in the range of 40-99.degree. C. with continuous mixing to obtain an oil in water microemulsion or sub-micron emulsion, c) allowing the microemulsion or sub-micron emulsion to cool, and d) adding a third part to the microemulsion or sub-micron emulsion at a temperature between 2.degree. C. and the phase assembly temperature, the third part if necessary being premixed and heated until the components are dissolved and comprising a non-surfactant amphiphilic type compound, that is a water miscible organic solvent and a pharmaceutically active ingredient that is insoluble or only sparingly soluble in water, wherein the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant is approximately 9.0:1.0 to 2.0:3.0. 2. The process according to claim 1 wherein the second part is added in two aliquots. 3. The process according to claim 2 wherein of the two aliquots one is about 70% by weight of the second part and another is about 30% by weight of the second part. 4. The process according to claim 1 wherein the pharmaceutically active ingredient is one or more water insoluble compounds selected from the group consisting of corticosteroids, desonide, clobetasol, betamethasone, vitamin D analogues and vitamin A analogues. 5. The process according to claim 1 wherein an occlusive agent is present in the first part. 6. The process according to claim 5 wherein the occlusive agent is petrolatum. 7. A process for the preparation of an oil in water (O/W) microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, the method comprising the successive steps of: a) heating a first part comprising at least one selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol; and at least one lipophilic surfactant to a temperature of 40-99.degree. C., and mixing to homogeneity, b) heating a second part comprising water and at least one hydrophilic surfactant to a temperature of 40-99.degree. C., and mixing to achieve homogeneity, c) adding the second part to the first part at a temperature of 40-99.degree. C., with continuous mixing whereby a microemulsion or sub-micron emulsion is formed at a phase assembly temperature, d) allowing the microemulsion or sub-micron emulsion to cool, and e) adding a third part to the microemulsion or sub-micron emulsion at a temperature between room temperature and the phase assembly temperature the third part having been premixed, and if necessary heated until the components are dissolved and comprising a non-surfactant amphiphilic type compound, that is a water miscible organic solvent and a pharmaceutically active ingredient that is insoluble or only sparingly soluble in water, wherein the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant is approximately 9.0:1.0 to 2.0:3.0. 8. The process according to claim 3 wherein the aliquot that is about 30% by weight of the second part is added after the microemulsion or sub-micron emulsion has formed, at a temperature below the temperature of the first aliquot, and at a rapid rate so as to reduce the overall temperature of the composition to below 60.degree. C. whereby the microemulsion or sub-micron emulsion structure is fixed. 9. The process according to claim 7 wherein the second part is added in two aliquots. 10. The process according to claim 9 wherein of the two aliquots one is about 70% by weight of the second part and another is about 30% by weight of the second part. 11. The process according to claim 10 wherein the aliquot that is about 30% by weight of the second part is added after the microemulsion or sub-micron emulsion has formed, at a temperature below the temperature of the first aliquot, and at a rapid rate so as to reduce the overall temperature of the composition to below 60.degree. C. whereby the microemulsion or sub-micron emulsion structure is fixed. 12. The process according to claim 7 wherein the pharmaceutically active ingredient is one or more water insoluble compounds selected from the group consisting of corticosteroids, desonide, clobetasol, betamethasone, vitamin D analogues and vitamin A analogues. 13. The process according to claim 7 wherein an occlusive agent is present in the first part. 14. The process according to claim 13 wherein the occlusive agent is petrolatum.